These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 39048807)

  • 1. MASCC/ISOO Clinical Practice Statement: Management of oral manifestations of chronic graft-versus-host-disease.
    Zadik Y; Raber-Durlacher JE; Epstein JB; Majorana A; Laheij A; Bardellini E; Blijlevens N; Elad S
    Support Care Cancer; 2024 Jul; 32(8):546. PubMed ID: 39048807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MASCC/ISOO Clinical Practice Statement: The risk of secondary oral cancer following hematopoietic cell transplantation.
    Raber-Durlacher JE; Treister NS; Zadik Y; Dean DR; Miranda-Silva W; Fregnani ER; Epstein JB; Elad S
    Support Care Cancer; 2024 Jul; 32(8):545. PubMed ID: 39048762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MASCC/ISOO Clinical Practice Statement: Management of salivary gland hypofunction and xerostomia in cancer patients.
    Hong C; Jensen SB; Vissink A; Bonomo P; Santos-Silva AR; Gueiros LA; Epstein JB; Elad S
    Support Care Cancer; 2024 Jul; 32(8):548. PubMed ID: 39048728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MASCC/ISOO Clinical Practice Statement: Clinical assessment of salivary gland hypofunction and xerostomia in cancer patients.
    Hong C; Epstein JB; Jensen SB; Gueiros LA; van Leeuwen SJM; Kandwal A; Vissink A; Elad S
    Support Care Cancer; 2024 Jul; 32(8):551. PubMed ID: 39048727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MASCC/ISOO clinical practice statement: Current understanding on controversies in basic oral care in hemato-oncology and hematopoietic cell transplantation.
    Raber-Durlacher JE; Zadik Y; Treister NS; Stempler N; Bruno JS; Epstein JB; Elad S
    Support Care Cancer; 2024 Jul; 32(8):550. PubMed ID: 39048882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MASCC/ISOO Clinical Practice Statement: Management of oral complications of targeted therapy.
    Villa A; Epstein JB; Yarom N; Hong C; Fulop C; Bossi P; Elad S
    Support Care Cancer; 2024 Jul; 32(8):549. PubMed ID: 39048808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral disease profiles in chronic graft versus host disease.
    Bassim CW; Fassil H; Mays JW; Edwards D; Baird K; Steinberg SM; Cowen EW; Naik H; Datiles M; Stratton P; Gress RE; Pavletic SZ
    J Dent Res; 2015 Apr; 94(4):547-54. PubMed ID: 25740857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral chronic graft-versus-host disease in Australia: clinical features and challenges in management.
    Hull K; Kerridge I; Avery S; McCullough M; Ritchie D; Szer J
    Intern Med J; 2015 Jul; 45(7):702-10. PubMed ID: 26134695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral chronic graft-versus-host disease: What the general dental practitioner needs to know.
    Haverman TM; Raber-Durlacher JE; Raghoebar II; Rademacher WMH; Rozema FR; Hazenberg MD; Epstein JB; Treister NS
    J Am Dent Assoc; 2020 Nov; 151(11):846-856. PubMed ID: 33121606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research.
    Mays JW; Fassil H; Edwards DA; Pavletic SZ; Bassim CW
    Oral Dis; 2013 May; 19(4):327-46. PubMed ID: 23107104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Oral chronic graft versus host disease, what is it and how is it treated?].
    Laheij AMGA; Raber-Durlacher JE; Hazenberg MD; Schoordijk MCE; Huysmans MCDNJM; de Visscher JGAM
    Ned Tijdschr Tandheelkd; 2022 Jul; 129(7-8):329-336. PubMed ID: 35833281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Complications of Chronic Graft-Versus-Host Disease.
    Fall-Dickson JM; Pavletic SZ; Mays JW; Schubert MM
    J Natl Cancer Inst Monogr; 2019 Aug; 2019(53):. PubMed ID: 31425593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MASCC/ISOO Clinical Practice Statement: Adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw.
    Yarom N; Van Poznak CH; Epstein JB; Ottaviani G; Matsuda Y; Migliorati C; Elad S
    Support Care Cancer; 2024 Jul; 32(8):547. PubMed ID: 39048887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chronic graft-versus-host-disease involving the oral mucosa: clinical presentation and treatment].
    Elad S; Levitt M; M Y S
    Refuat Hapeh Vehashinayim (1993); 2008 Nov; 25(4):19-27, 72. PubMed ID: 19263864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical approach in the management of oral chronic graft-versus-host disease (cGVHD) in a series of specialized medical centers.
    Elad S; Jensen SB; Raber-Durlacher JE; Mouradian N; Correa EM; Schubert MM; Blijlevens NM; Epstein JB; Saunders DP; Waltimo T; Yarom N; Zadik Y; Brennan MT
    Support Care Cancer; 2015 Jun; 23(6):1615-22. PubMed ID: 25417041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease.
    Fall-Dickson JM; Mitchell SA; Marden S; Ramsay ES; Guadagnini JP; Wu T; St John L; Pavletic SZ;
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):948-956. PubMed ID: 20139026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD.
    Meier JK; Wolff D; Pavletic S; Greinix H; Gosau M; Bertz H; Lee SJ; Lawitschka A; Elad S;
    Clin Oral Investig; 2011 Apr; 15(2):127-39. PubMed ID: 20859645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review of Oral Chronic Graft-Versus-Host Disease: Considerations for dental hygiene practice.
    Johnson LB; Oh U; Rothen M; Sroussi HY; Dean DR; Lloid CM; Cintron K; Lee SJ; Cutler CS; Treister NS
    J Dent Hyg; 2022 Apr; 96(2):6-17. PubMed ID: 35418491
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral cGVHD screening tests in the diagnosis of systemic chronic graft-versus-host disease.
    Resende RG; de Fátima Correia-Silva J; Arão TC; Brito JA; Bittencourt H; Gomez RS; Abreu MH
    Clin Oral Investig; 2012 Apr; 16(2):565-70. PubMed ID: 21369795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salivary Gland Hypofunction and/or Xerostomia Induced by Nonsurgical Cancer Therapies: ISOO/MASCC/ASCO Guideline.
    Mercadante V; Jensen SB; Smith DK; Bohlke K; Bauman J; Brennan MT; Coppes RP; Jessen N; Malhotra NK; Murphy B; Rosenthal DI; Vissink A; Wu J; Saunders DP; Peterson DE
    J Clin Oncol; 2021 Sep; 39(25):2825-2843. PubMed ID: 34283635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.